Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash & Equivalents (2016 - 2026)

Standard Biotools has reported Cash & Equivalents over the past 16 years, most recently at $120.9 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 27.51% to $120.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120.9 million through Dec 2025, down 27.51% year-over-year, with the annual reading at $120.9 million for FY2025, 27.51% down from the prior year.
  • Cash & Equivalents was $120.9 million for Q4 2025 at Standard Biotools, down from $129.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $288.3 million in Q1 2024 and troughed at $29.5 million in Q4 2021.
  • The 5-year median for Cash & Equivalents is $98.4 million (2022), against an average of $114.0 million.
  • Year-over-year, Cash & Equivalents plummeted 58.66% in 2021 and then soared 269.23% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $29.5 million in 2021, then skyrocketed by 179.38% to $82.3 million in 2022, then tumbled by 36.23% to $52.5 million in 2023, then soared by 217.58% to $166.7 million in 2024, then dropped by 27.51% to $120.9 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cash & Equivalents are $120.9 million (Q4 2025), $129.4 million (Q3 2025), and $158.6 million (Q2 2025).